Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medical Developments International (ASX:MVP) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Medical Developments International's Enterprise Value for the quarter that ended in Jun. 2026 was A$24.80 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Medical Developments International's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was A$0.57 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medical Developments International EV-to-EBIT Related Terms
Medical Developments International EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medical Developments International EV-to-EBIT Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Medical Developments International's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medical Developments International EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Medical Developments International's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Medical Developments International's EV-to-EBIT falls into.
Medical Developments International's current Enterprise Value is A$33.81 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Medical Developments International's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was A$0.57 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medical Developments International (ASX:MVP) has a EV-to-EBIT of 59.42 as of Sep. 08, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Medical Developments International and its competitors. This is 52% below median its historical median of 122.86. According to the industry distribution chart, Medical Developments International ranks #594 out of 681 companies in the Drug Manufacturers industry, placing it in the top 87.2%.
Is Medical Developments International's EV-to-EBIT too high?
Medical Developments International's current EV-to-EBIT of 59.42 is 52% below median its 10-year median of 122.86. The Drug Manufacturers industry median EV-to-EBIT is 16.01. Medical Developments International's value of 59.42 is 271.1% above this industry median. Based on the distribution chart, Medical Developments International ranks #594 out of 681 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Medical Developments International has a GF Score™ of 54/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Medical Developments International's EV-to-EBIT compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Medical Developments International ranks #594 out of 681 companies for EV-to-EBIT. This places Medical Developments International in the lower half of its industry. The industry median EV-to-EBIT is 16.01. Medical Developments International's value of 59.42 is 271.1% above this benchmark. While the company's 10-year median is 122.86 vs. the industry median of 16.01, Medical Developments International has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 16.01, based on 681 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medical Developments International's current EV-to-EBIT of 59.42 is 271.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Medical Developments International and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 16.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medical Developments International's current EV-to-EBIT is 59.42, which is 52% below median its own 10-year median of 122.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medical Developments International stock overvalued right now?
Based on GuruFocus' analysis, Medical Developments International (ASX:MVP) is currently considered Fairly Valued. The stock's GF Value™ is A$0.53, compared to a current price of A$0.50 — trading 5.7% below its estimated fair value. The current EV-to-EBIT is 59.42, which is 52% below median its 10-year median of 122.86 and 271.1% above the Drug Manufacturers industry median of 16.01. Medical Developments International's overall GF Score™ is 54/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Medical Developments International (ASX:MVP), the current EV-to-EBIT is 59.42 as of Sep. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medical Developments International (ASX:MVP) Overvalued in 2026?
Based on GuruFocus' analysis, Medical Developments International stock appears to be undervalued.
The current stock price of A$0.50 is trading 5.7% below its estimated GF Value™ of A$0.53.
GuruFocus considers Medical Developments International to be Fairly Valued.
Key valuation signals for ASX:MVP:
EV-to-EBIT: 59.42 (52% below median its 10-year median of 122.86)
GF Value™: A$0.53 vs. price of A$0.50 (5.7% below fair value)
Industry Position: 271.1% above the Drug Manufacturers median (#594 of 681)
No single metric tells the full story. See the ASX:MVP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medical Developments International Ltd is a specialized healthcare company. The Company manufactures and distributes Penthrox, a fast-acting trauma and emergency pain relief product, used in hospital emergency departments, ambulance services, sports medicine, and for analgesia during short surgical procedures. The segments of the company are Pain Management and Respiratory. The company derives maximum revenue from the Pain management segment.
54GF Score
Get the complete analysis for ASX:MVP
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:MVP has been successfully added to your 
